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Objectives. To determine incidentally found prostate cancer frequency and impact on overall survival after RCP. Patients and
Methods. The records of 81 men who underwent cystoprostatectomy from January 2000 to December 2009 were reviewed. The
vital status of the study group was assessed as on September 1, 2009, by passive followup, using data from the population registry.
Results.The81menunderwent RCP.Theincidental prostatecancer wasfoundinthespecimensof27(33.3%)patients.13(48.1%)
of 27 prostate cancer cases were clinically signiﬁcant. For 3 patients (11.1%) an extraprostatic extension was found. For 2 patients
(7.4%)—positive margins, for 1 patient (3.7%)—Gleason sum 8, and for the rest 7 patients bigger than 0.5cm3 volume tumor,
and Gleason sum 7 was found. The mean follow-up time was 39.2 ± 33.8 months (varies from 0.8 to 131.2 months). The patients
with bladder cancer and incidentally found prostate cancer lived shorter (28.1 ± 27.5a n d4 5 .5 ± 35.40 months). Higher overall
survival(P = 0.03)wasfoundinthepatientgroupwithbladdercancerwithoutincidentallydiagnosedprostatecancer. Conclusion.
There are indications that in this small study prostate cancer has inﬂuenced on patients’ survival with bladder cancer after radical
cystoprostatectomy.
1.Introduction
Bladdercanceristhesecondmostcommoncancerofurinary
tract after prostate cancer and the fourth most common
malignancy in men [1]. Although the disease may occur in
young persons, about 78% of all cancers are diagnosed in
personsofage55y earsandolder[2].70%ofallpatientswith
bladder cancer have superﬁcial cancer that does not reach
the muscular layer, and most of these patients have a fairly
good prognosis. Most of the patients with superﬁcial bladder
cancer have pTa bladder cancer stage. 20% of all patients
with bladder cancer have pT1 bladder cancer stage and just
10% is carcinoma in situ [3]. Patients with carcinoma in situ
have the biggest risk of cancer progression into the muscular
layer and also are in the biggest risk group of death. Radical
cystoprostatectomy (RCP) is the standard and eﬀective
treatmentmethodforthepatientswithinvasiveorsuperﬁcial
recurrent bladder cancer who are in a high progression risk
group. Patients’ survival after RCP depends on the primary
tumor grade and stage. 5-year survival after RCP varies from
33 to 73%, and no other medical attempts during the last 10
years had no inﬂuence for patients’ survival [4]. The standart
technique of RCP in men consists of removing a bladder
together with the removal of a prostate, seminal vesicles,
a part of the vasa deferentia and distal ureter, including
regionallymphadenectomy.Incommoncases,RCPisrelated
with a sexual and urinary disfunction. In order to preserve
patients’ erectile function, urination and the quality of life
associated with RCP, the new sparing techniques of prostate
have been described, including procedures that spare the
apex, the prostatic capsule and seminal vesicle, and even the
total prostate with neurovascular bundle [5–7]. Preserved
autonomic and sensory pelvic nerves can determine better
urination and potency results. On the other hand, all these2 Prostate Cancer
modiﬁcations of RCP are associated with non radical cancer
elimination in those cases when prostate cancer or local
urotel carcinoma invasion to prostate or prostatic uretra
part was not diagnosed before the operation [8, 9]. After
RCP, incidental prostate cancer is diagnosed from 23 to
54% of patients and has not clear clinical inﬂuence [10,
11]. Incidentally found prostate cancer is classiﬁed into
two groups: clinical signiﬁcant and clinical insigniﬁcant
prostate cancer. This classiﬁcation does not show the exact
malignancy of prostate cancer because it is caused by many
other factors [12, 13]. Prostate cancer is clinical signiﬁ-
cant when there is positive tumor margins, extraprostatic
extension, Gleason score is more than 6 or tumor volume
is 0.5cm3 or bigger. Perineural invasion is one of clinical
signiﬁcant prostate cancer signs which show a biological
malignancy and recurrence risk [14, 15]. There are not many
studies where the inﬂuence of incidentally found prostate
cancer for patients’ overall survival was examined. In those
studies, where the inﬂuence of incidentally found prostate
cancer for overall survival was examined, the majority of
all clinical signiﬁcant prostate cancer cases could not be
stratiﬁed as clinically signiﬁcant because those cases did not
satisfywiththelatter-dayclinicallysigniﬁcantprostatecancer
conception. With this retrospective analysis, we wanted to
evaluate incidentally found prostate cancer frequency after
RCP, histopathological characteristics of it, and incidental
prostate cancer impact on patients’ overall survival.
2. Patientsand Methods
The records of 81 men who underwent RCP for transitional
cell carcinoma of a bladder at our institution from January
2000 to December 2009 were reviewed. The incidental
prostate cancer was found in the specimens of 27 (33.3%)
patients (with a mean age at surgery of 61.3 ±8.0), and their
pathological and clinical records were analyzed. 7 patients
with a known history of prostate cancer were excluded.
A routine pathological examination was used for all RCP
specimens, by sectioning and totally submitting the bladder
andprostatetissue.Soonaftertheoperation,theprostatewas
severed from the bladder and then prostates were weighed,
inked, and ﬁxed in 10% formalin. After ﬁxation the prostate
specimens were sectioned at 3mm intervals perpendicular
to the apical-basal axis of the gland. The seminal vesicles
were sectioned parallel to their junction with the prostate.
The volume of cancer was determined by the grid-counting
method [16, 17]. The sum of the area of each slice was
multiplied by the average slice thickness, and the sum of
thesevolumes wasmultiplied by1.25toaccountforformalin
shrinkage. All cancers were graded according to the Gleason
system. The 1997 TNM (tumor, nodes, and metastasis)
system was used for pathologic staging. Surgical margins
were considered positive when cancer cells were in contact
with the inked margin. Extraprostatic extension was deﬁned
as cancer extending into extraprostatic tissue. The numeric
variables were presented as mean ± SD. The vital status of
the study group was assessed as on September 1, 2009, by
passive followup, using data from the population registry.
It was found that 20 (33.9%) of the patients had died.
Survival was estimated by the Kaplan-Meier method, and
diﬀerences were assessed with the log-rank statistic. P<
0.05 indicated a signiﬁcant statistical diﬀerence. For between
groups, comparison of categorical variables was used chi-
square test. All statistical analyses were performed using
Stata Statistical Software version 11 (StataCorp. 2009. Stata
Statistical Software: Release 11. College Station, TX, USA).
3. Results
The mean age of patients with prostate cancer was 60.6 years;
without prostate cancer 62.8 years. Statistically signiﬁcant
diﬀerence between patients age in those two groups was
not found. Incidentally found prostate cancer rate in inves-
tigated group was 33.3% (27 patients). Table 1 shows the
histopathological characteristics of prostate cancer. For 14
patients (51.8%), tumor was found in both prostate’s lobes,
and for the rest 10 (48.2%) patients prostate cancer was
diagnosed just in one lobe. 13 (48.1%) of 27 prostate cancer
cases were clinically signiﬁcant. For 3 patients (11.1%) in
clinical signiﬁcant cancer group an extraprostatic extension
was found during the histopathological examination. For 2
patients (7.4%)—positive margins, for 1 patient (3.7%)—
Gleason sum 8, and for the rest 7 patients the bigger than
0,5cm3 volumecancerwithGleasonsum7wasfoundduring
the ﬁnal histopathological examination.
19 patients (70.3%) had prostate cancer with Gleason
sum6.Gleasonsum7wasdiagnosedfor2patientswithpT3a
bladder cancer and for 2 patients with pT2a bladder cancer.
Clinically signiﬁcant cancer was associated with higher
Gleason sum, risk of extraprostatic extension and positive
margins. For 3 cases from all 27 patients with prostate cancer
were histopathologically diagnosed metastases from bladder
cancer to lymphatic nodes. Table 2 shows histopathological
characteristic of bladder cancer. 3 patients (11.1%) with
incidentally found prostate cancer had a superﬁcial bladder
cancer. For 2 patients (7.4%) from 27 patients group
with prostate cancer, a pT2a bladder cancer stage was
diagnosed. For 4 patients in this group (14.8%) pT2b, for
8 (29.6%)—pT3a, for 1 (3.7%)—pT3b, for 8 (29.6%)—
pT4a, and for 1 (3.7%)—pT4b, bladder cancer stages were
diagnosed. For 9 patients (16.6%) with bladder cancer and
without prostate cancer, a superﬁcial bladder cancer was
diagnosed. For 10 patients in this group (18.5%)—pT2a,
for 2 (3.7%)—pT2b, for 12 (22.2%)—pT3a, for 5 (9.2%)—
pT3b, for 8 (14.8%)—pT4a, and for 8 (14.8%)—pTis,
bladder cancer stages were diagnosed. Statistically signiﬁcant
diﬀerence between bladder cancer stage, cancer malignancy
and positive lymphatic odes was not found between two
groups. The mean follow-up time was 39.2 ± 33.8 months
(varies from 0.8 to 131.2 months) (Figure 1). Patients with
bladder cancer and incidentally found prostate cancer lived
shorter than patients without prostate cancer (28.1 ± 27.5
and 45.5±35.40 months). Higher overall survival (P = 0.03)
wasfound in the patient’s groupwith bladdercancerwithout
incidentally diagnosed prostate cancer (Figure 2).Prostate Cancer 3
Table 1: The histological characteristics of the 27 prostate cancers identiﬁed in the 81 RCP specimens.
Number of patients Signiﬁcant tumour Tumour at apex Positive SM
(% of total) (% of total) (% of total) (% of total)
Ts t a g e( T N M )
pT1a 1 (3.7) 0 (0) 0 (0) 0 (0)
pT2a 7 (25.9) 0 (0) 0 (0) 0 (0)
pT2b 2 (7.4) 1 (3.7) 0 (0) 0 (0)
pT2c 14 (51.8) 9 (33.3) 7 (25.9) 1 (3.7)
pT3a 3 (11.1) 3 (11.1) 3 (11.1) 1 (3.7)
Total 27 (100) 13 (48.1) 10 (37.0) 2 (7.4)
Gleason score
2–6 19 (70.3) 3 (11.1) 2 (7.4) 0 (0)
7 7 (25.9) 9 (33.3) 7 (25.9) 1 (3.7)
8–10 1 (3.7) 1 (3.7) 1 (3.7) 1 (3.7)
Total 27 (100) 13 (48.1) 10 (37.0) 2 (7.4)
Lymph node classiﬁcation
N0 27 (100)
N1 0( 0 )
Table 2: The pathological stages of bladder primary tumours.
Variable Prostate Ca + Prostate Ca −
Number of patients Percentage of total Number of patients Percentage of total
Ts t a g e( T N M )
pTa 1 3.7 4 7.4
pT1 2 7.4 5 9.2
pT2a 2 7.4 10 18.5
pT2b 4 14.8 2 3.7
pT3a 8 29.6 12 22.2
pT3b 1 3.7 5 9.2
pT4a 8 29.6 8 14.8
pT4b 1 3.7 0 0
pTis 0 0 8 14.8
Grade
G1 0 0 2 3.7
G2 3 11.1 3 5.5
G3 24 88.9 49 90.7
Lymph node classiﬁcation
N0 24 88.9 47 87.0
N1 3 11.1 7 13.0
4. Discussion
Incidentally found prostate cancer is diagnosed during the
pathological test after surgical intervention (radical cysto-
prostatectomy, etc.) for the patients without any symptoms
or for those patients for whom this disease was not suspected
during the physical examination (DRT) or the estimating
laboratorial (PSA) and instrumental (prostate biopsy) tests.
More than a half of all incidentally found prostate cancers
and more than 90% of all prostate cancer inﬂuenced deaths
occur for the patients who are 65 years old or older [10]. It is
thought, that these facts are related with a worse Gleason’s
diﬀerentiation and clinical or pathological prostate cancer
stage. Prostate cancer treatment with radical prostatectomy
has limited use for older patients because of a higher risk of
cancermetastasistilladiseaseisdiagnosed[11].Thepossible
relation between prostate and bladder cancers is stated in
many diﬀerent studies [18–21]. Prostate cancer is diagnosed
nine times more for men with bladder cancer. If not to count
the mistakes of cases inclusion, prostate cancer is nineteen
times more often between patients with bladder cancer than
by age, sex, or race in adequate population [20]. Relation
between these two cancers can be explained by genetical
factors. It is known that the birth of both cancers is related
with pathology of P53 and Rb genes.4 Prostate Cancer
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The rate of incidentally found cancer is inﬂuenced by
studied population. Lee et al. [22] shows that just for 4%
of all 248 studied patients incidentally found prostate cancer
was found in Taiwan. A bit more cases of incidentally
found cancer were found in the Kurahashi et al. [23]s t u d y .
IncidentallyfoundcancerafterRCPwasdiagnosedfor33.3%
of all examined patients in our study. It is similar to many
other studies which were made in Western Europe countries.
In these studies, rate of incidentally found prostate cancer
wasfrom23%to51%[10,11].Themostimportantcriterion
for incidentally found prostate cancer is clinically signiﬁcant
prostate cancer. There is no deﬁnition of clinically signiﬁcant
prostate cancer, but it is thought that it is related with a
higherriskoflocalrelapseormetastasis.Therateofclinically
signiﬁcant prostate cancer is from 14% to 53% [24, 25]. Such
a wide variety of clinically signiﬁcant cancer is inﬂuenced
by studied population, the protocol of histopathological test
and by the deﬁnition of clinically signiﬁcant prostate cancer.
The rate of clinically signiﬁcant cancer in our study reaches
48.1%. For 3 (11.1%) patients extraprostatic extension, for
2 (7.4%)—positive margins, for 1 (3.7%)—Gleason sum
8 tumor, and for the rest 7—bigger than 0.5cm3 volume
tumor were diagnosed during histopathological tests. More
and more often prostate sparing RCP, which improve sexual
and urination function, are performed [20]. There are few
authors, who recommend to perform prostate capsule or top
sparing ECP for improving sexual and urination functions
[5–7]. These operations can be related with neither the
radical elimination of tumor nor a higher risk of positive
margins and worse oncological results. By the way, that risk
is higher than tumor is on the top of prostate. For 37.0% of
all patients in our study, prostate cancer was found on the
top of prostate. There are no many studies where inﬂuence
for patients’ survival of incidentally found prostate cancer
after RCP was examined. Abdelhady et al. [14] found that
the combination of prostate and bladder cancers has no
inﬂuence on patients’ survival prognosis and is related with
one or another cancer stage. Pritchett et al. [26] also found
that the patients with bladder cancer and incidentally found
prostate cancer are not in a higher risk of death than patients
who have only bladder cancer. Kouriefs et al. [27]i nv e r y
small undertake study found that incidentally found prostate
cancer is really frequent ﬁnding and has no inﬂuence for
overall survival after radical elimination of cancer. Similar
results were found in other studies [28, 29]. The problem
is that clinically signiﬁcant prostate cancer deﬁnition in
these studies is contravening with nowadays conception, or
mean time of patients observation was very short. There
was no statistically signiﬁcant diﬀerence between patients
age, pathological stage, or number of positive lymphatic
nodes in our study. Our study showed what overall survival
for the patients with incidentally found prostate cancer was
28.1±27.5monthsversus 45.5±35 (p−0.03)forthepatients
without prostate cancer, respectively. Our study shows that
incidentallyfoundprostatecancerhasaninﬂuenceonoverall
survival, that is why it is important to pay more attention to
this pathology. For all the patients for whom is planned to
perform modiﬁed radical prostatectomy, prostate biopsy is
recommended even if PSA concentration is normal. Prostate
biopsy will allow choosing a more suitable treatment for
bladder cancer, will reduce the risk of positive margins
and the progression of prostate cancer, and will improve
oncological outcomes. It is necessary to have more wide
amount studies, which could conﬁrm our ﬁndings.
5. Conclusion
Incidentally found prostate cancer is often found after the
radical cystoprostatectomy. There are indications that in
this small study prostate cancer has inﬂuence on patients’
survivalwithbladdercancerafterradicalcystoprostatectomy.
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